214 related articles for article (PubMed ID: 12553015)
1. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
3. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
Grosios K; Loadman PM; Swaine DJ; Pettit GR; Bibby MC
Anticancer Res; 2000; 20(1A):229-33. PubMed ID: 10769660
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
7. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
8. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
9. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.
Iyer S; Chaplin DJ; Rosenthal DS; Boulares AH; Li LY; Smulson ME
Cancer Res; 1998 Oct; 58(20):4510-4. PubMed ID: 9788591
[TBL] [Abstract][Full Text] [Related]
12. Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice.
Sun L; Vasilevich NI; Fuselier JA; Coy DH
Anticancer Res; 2004; 24(1):179-86. PubMed ID: 15015595
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503.
Hill SA; Toze GM; Pettit GR; Chaplin DJ
Anticancer Res; 2002; 22(3):1453-8. PubMed ID: 12168822
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
Pettit GR; Toki B; Herald DL; Verdier-Pinard P; Boyd MR; Hamel E; Pettit RK
J Med Chem; 1998 May; 41(10):1688-95. PubMed ID: 9572894
[TBL] [Abstract][Full Text] [Related]
15. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
Brooks AC; Kanthou C; Cook IH; Tozer GM; Barber PR; Vojnovic B; Nash GB; Parkins CS
Anticancer Res; 2003; 23(4):3199-206. PubMed ID: 12926054
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.
Pettit GR; Lippert JW
Anticancer Drug Des; 2000 Jun; 15(3):203-16. PubMed ID: 11049088
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
Shnyder SD; Cooper PA; Pettit GR; Lippert JW; Bibby MC
Anticancer Res; 2003; 23(2B):1619-23. PubMed ID: 12820431
[TBL] [Abstract][Full Text] [Related]
19. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
Ohsumi K; Nakagawa R; Fukuda Y; Hatanaka T; Morinaga Y; Nihei Y; Ohishi K; Suga Y; Akiyama Y; Tsuji T
J Med Chem; 1998 Jul; 41(16):3022-32. PubMed ID: 9685242
[TBL] [Abstract][Full Text] [Related]
20. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM
Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
